140410 — Mezzion Pharma Co Income Statement
0.000.00%
Last trade - 00:00- KR₩3tn
- KR₩3tn
- KR₩8bn
Annual income statement for Mezzion Pharma Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 26,654 | 30,726 | 31,721 | 8,612 | 7,910 |
| Cost of Revenue | |||||
| Gross Profit | 3,698 | -313 | 3,884 | 1,910 | 1,452 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 43,451 | 54,057 | 46,059 | 22,911 | 24,750 |
| Operating Profit | -16,798 | -23,331 | -14,338 | -14,300 | -16,840 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -13,026 | -35,910 | -12,480 | -14,534 | -38,838 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -13,603 | -36,298 | -12,728 | -19,477 | -34,929 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -13,603 | -36,298 | -12,728 | -19,477 | -34,929 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -13,603 | -36,298 | -12,728 | -19,477 | -34,929 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -510 | -1,001 | -454 | -643 | -1,159 |
| Dividends per Share |